Concepedia

Benefit-risk Endpoints

Benefit-Risk Endpoints is a formal construct in regulatory decision science that specifies the distinct, measurable outcomes used to evaluate and compare the therapeutic advantages and adverse effects of medical interventions within a benefit-risk assessment framework.

149

Publications

9.3K

Citations

887

Authors

524

Institutions

Publications per year

2017–2026

56

Parents

Publications

149

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

Thomas R. E. Barnes, Richard Drake, Carol Paton et al. · Journal of Psychopharmacology · 2019 · 596 citations · Full text

, , +13

Biomarkers and surrogate endpoints in clinical trials

Thomas R. Fleming, John H. Powers · Statistics in Medicine · 2012 · 530 citations

, , +11

Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years

Gruppo Italiano Studio Policitemia · Annals of Internal Medicine · 1995 · 504 citations

, , +14

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts et al. · Journal of Clinical Oncology · 2017 · 482 citations

, , +16

Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline

Marie B. Demay, Anastassios G. Pittas, Daniel D. Bikle et al. · The Journal of Clinical Endocrinology & Metabolism · 2024 · 460 citations · Full text

, , +14

1–5 of 149

Authors

887

  1. LD
    Lawrence D. Phillips

    London School of Economics and Political Science, United Kingdom

    5 publications · 136 citations

    5

    h-index

  2. IV
    I. V. Gribovskaya

    Institute of Biophysics, Russia

    3 publications · 120 citations

    3

    h-index

  3. ON
    Olesia N. Makhutova

    Institute of Biophysics, Russia

    3 publications · 120 citations

    3

    h-index

  4. MI
    Michail I. Gladyshev

    Institute of Biophysics, Russia

    3 publications · 120 citations

    3

    h-index

  5. BL
    Bennett Levitan

    Janssen (United States), United States

    3 publications · 114 citations

    3

    h-index

1–5 of 887

Institutions

524

  1. Harvard University

    Cambridge, United States

    9 h-index

    18 publications

    2.2K citations

  2. Eli Lilly (United States)

    Indianapolis, United States

    7 h-index

    34 publications

    11.4K citations

  3. University of Copenhagen

    Copenhagen, Denmark

    5 h-index

    11 publications

    312 citations

  4. Johns Hopkins University

    Baltimore, United States

    5 h-index

    7 publications

    321 citations

  5. London School of Economics and Political Science

    London, United Kingdom

    4 h-index

    4 publications

    165 citations

  6. Bayer (United States)

    Whippany, United States

    4 h-index

    25 publications

    10.7K citations

  7. University of Manchester

    Manchester, United Kingdom

    4 h-index

    11 publications

    2.7K citations

  8. Pfizer (United States)

    New York, United States

    4 h-index

    30 publications

    11.1K citations

1–8 of 524

Venues

  1. PubMed

    Repository · 9 publications · 444 citations

    9

    h-index

  2. Pharmacoepidemiology and Drug Safety

    4 publications · 179 citations

    4

    h-index

  3. Value in Health

    4 publications · 172 citations

    4

    h-index

  4. PLoS ONE

    3 publications · 125 citations

    3

    h-index

  5. Multiple Sclerosis Journal

    MSJ · 3 publications · 175 citations

    3

    h-index

1–5